An essential approach in integrative healthcare involves the strategic combination of targeted modalities that work together to increase benefits of conventional therapies. This is particularly essential when addressing cellular health.
A 2017 preclinical study published in BMC Complementary and Alternative Medicine demonstrates that a breast health dietary supplement offers significant support in this area, specifically against the growth of aggressive breast cells.
Performed at the Methodist Research Institute, Indiana University Health, this study highlights the ability of the breast formula to boost the effects of tamoxifen—a hormonal protocol used for cellular breast health—against estrogen receptor-positive (ER-positive) breast cells. This is the fourth published study on this physician-formulated supplement, and the first using ER-positive cells, to demonstrate the vital breast health benefits of this unique formula.*
These outstanding results were also presented June 2019, at the ICCR-2019.
Strategy for Success
In this study, the researchers tested tamoxifen and the supplement alone, and then in combination against human breast cell line, MCF-7. Alone, the supplement worked as well as tamoxifen against MCF-7 cells.
Together, however, the combination produced more significant effects, by influencing the expression of genes associated with specific cellular mechanisms. Tissues from a xenograft (human breast cells grafted to mice mammary tissue) mouse model showed significant improvement compared to the control group.
This unique breast health formula is a combination of a bioavailable form of turmeric extract, diindolylmethane (DIM), which is an active metabolite usually obtained from eating cruciferous vegetables, extracts of Astragalus membranaceus and Scutellaria barbata, quercetin, and several species of beneficial mushrooms cultivated on a blend of immune and cellular-supportive herbs.
As a researched breast health supplement, this formula has been shown in previous studies to support breast cellular function and prevent migration of triple-negative breast cells, through the regulation of specific genes and cellular mechanisms. However, this is the first study demonstrating the ability of the formula to enhance conventional approaches, further substantiating its importance in hormone-positive, as well as hormone-negative breast health protocols.*
*These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.